Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Vildagliptin 50 mg vs Galvus 50 mg in Healthy Volunteers
NCT05329844Phase 1Completed
- Sponsor
- AET Laboratories Private Limited
- Start
- Feb 2014
- Primary completion
- Mar 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AET Laboratories Private Limited. Primary endpoints: Maximum Plasma Concentration up to 24 hours and Area Under the Curve from time 0 to last measurable concentration up to 24 hours. Started Feb 2014; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05329844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329844.